Perlmutter Cancer Center

The purpose of the study is to evaluate the anti-tumor activity of ITu injections of mRNA-2752 alone and in combination with intravenously administered durvalumab in patients with histologically confirmed advanced or metastatic solid tumor malignancies or lymphoma. The study includes three treatment arms: Arm A: mRNA-2752 alone, Arm B: mRNA-2752 in combination with durvalumab (PD-L1 inhibitor), Arm C: mRNA-2752 alone or in combination with durvalumab. We want to find out the maximum tolerated dose or recommended dose for ITu injections of mRNA-2752 alone and in combination with durvalumab. The study drug mRNA-2752 alone and in combination with intravenously administered durvalumab are investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent and combination in the current trial.